The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial. Upon completion of the merger, the combined ...

Dianthus Therapeutics’ latest deal arrives as momentum builds behind its share price, with a 76% return over the past 90 days and a year-to-date share price return of 55%. While the total shareholder ...

Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics DNTH, expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin and ...

All Strongholds in Diablo 4 come with their end boss that you must defeat if you want to complete the Stronghold. One of the Strongholds in Diablo 4 is Vyeresz, defended by the boss Dianthus. This ...

Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...

Investing.com - Raymond James raised its price target on Dianthus Therapeutics (NASDAQ:DNTH) to $63.00 from $56.00 on Monday, while maintaining an Outperform rating on the stock. The company, ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best fast money stocks to buy now. Clear Street assumed coverage on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) with a ‘Buy’ rating and a price ...

Shares of Dianthus TherapeuticsDNTH surged to an 18-month high Monday after the company's autoimmune disease treatment succeeded in a midstage study. Now, Dianthus is planning to send its drug, ...

Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bispecific antibody designed to treat certain autoimmune disorders. Under the terms of the ...